Rye Brook Capital
PPH icon

Rye Brook Capital’s VanEck Pharmaceutical ETF PPH Stock Holding History

Rye Brook Capital’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.69M Buy
70,255
+2,925
+4% +$326K 4.98% 5
2026
Q2 		$7.36M Buy
+67,330
New +$6.97M 5.16% 5

Other funds holding PPH

J. Safra Asset Management
J. Safra Asset Management New York $2.3B AUM 21.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Adamsbrown Wealth Consultants
Adamsbrown Wealth Consultants Wichita, Kansas $548M AUM 16.52% 1-Year Est. Return
Miller Investment Management
Miller Investment Management West Conshohocken, Pennsylvania $1.13B AUM 13.3% 1-Year Est. Return
Old National Bancorp
Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return
WT Wealth Management
WT Wealth Management Scottsdale, Arizona $357M AUM 15.82% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return
Fortis Group Advisors
Fortis Group Advisors Westwood, New Jersey $623M AUM 25.42% 1-Year Est. Return

Rye Brook Capital's PPH Position: Q3 2026 in Review

Rye Brook Capital increased its VanEck Pharmaceutical ETF (PPH) stake by 4.3% in Q3 2026, buying an estimated $326K and bringing the position to 70,255 shares worth $7.69M. The position accounts for 4.98% of the portfolio, ranked #5.

Rye Brook Capital first reported a position in PPH in Q2 2026 and has held it in 2 quarters since. 97 funds tracked by Wall St. Rank hold PPH as of Q3 2026.

  • Rye Brook Capital held 70,255 shares of VanEck Pharmaceutical ETF worth $7.69M as of Q3 2026.
  • Rye Brook Capital bought 2,925 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $326K.
  • VanEck Pharmaceutical ETF made up 4.98% of Rye Brook Capital's portfolio in Q3 2026, its #5 holding.
  • Rye Brook Capital first reported a position in VanEck Pharmaceutical ETF in Q2 2026 and has held it in 2 quarters since.
  • 97 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.

Based on Rye Brook Capital's 13F filing for Q3 2026, filed 7 Oct 2026.